BioSig Technologies, Inc. (OTCMKTS:BSGM) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
time, to present and/or distribute to the investment community
and utilize at various industry and other conferences a slide
presentation, which is attached hereto as Exhibit 99.1. The
Company undertakes no obligation to update, supplement or amend
the materials attached hereto as Exhibit 99.1.
information in this Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Exchange Act or the
Securities Act of 1933, as amended, except as shall be expressly
set forth by reference in such a filing. Furthermore, the
furnishing of information under Item 7.01 of this Current Report
on Form 8-K is not intended to constitute a determination by the
Company that the information contained herein, including the
exhibits hereto, is material or that the dissemination of such
information is required by Regulation FD.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Investor Presentation, dated 2017 (furnished herewith to
Item 7.01) |
About BioSig Technologies, Inc. (OTCMKTS:BSGM)
BioSig Technologies, Inc. is a development-stage medical device company. The Company is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System. PURE EP System is a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The Company’s PURE EP System is designed to assist electrophysiologists with real-time evaluations of electrocardiograms and electrograms, and helps in making clinical decisions in real-time. It is also developing signal-processing tools, which will assist electrophysiologists in differentiating true signals from noise and provide guidance in identifying ablation targets within the PURE EP System. BioSig Technologies, Inc. (OTCMKTS:BSGM) Recent Trading Information
BioSig Technologies, Inc. (OTCMKTS:BSGM) closed its last trading session down -0.01 at 1.58 with 103,388 shares trading hands.
